Merck & Co., Inc. (MRK) operating KPIs
MRKNYSEPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 7, 2026Score 9/30242% above fair value
$146.33+5.40 (+3.83%)
Close on Oct 29, 2026Market cap $361.02BP/E 117.1Yield 2.24%
Merck belsomra (suvorexant — insomnia orexin receptor antagonist) — Worldwide sales ($M) ($M)
Form 10-Q / 10-K Segment & Product Sales Footnote & Form 8-K Table 3 / 3a / 3b
Latest, FY2025
186
Period ended Dec 31, 2025
Change on a year earlier
-16.2%
222 in FY2024
History
10 years
Since FY2016
Sources
9
Documents cited below
Annual history
Hover a value to see the sentence it was read from; calculated values show their formula
| Period | Ended | Belsomra (suvorexant — insomnia orexin receptor antagonist) — Worldwide sales ($M) ($M) | Year on year | Source |
|---|---|---|---|---|
| FY2025 | Dec 31, 2025 | 186 | -16.2% | Form 8-K (tm264564d1_ex99-1.htm, filed 2026-02-03) ↗ |
| FY2024 | Dec 31, 2024 | 222 | -3.9% | Form 8-K (tm264564d1_ex99-1.htm, filed 2026-02-03) ↗ |
| FY2023 | Dec 31, 2023 | 231 | -10.5% | Form 8-K (tm255059d1_ex99-1.htm, filed 2025-02-04) ↗ |
| FY2022 | Dec 31, 2022 | 258 | -18.9% | Form 8-K (tm244517d1_ex99-1.htm, filed 2024-02-01) ↗ |
| FY2021 | Dec 31, 2021 | 318 | -2.8% | Form 8-K (tm2227726d1_ex99-1.htm, filed 2022-10-27) ↗ |
| FY2020 | Dec 31, 2020 | 327 | +6.9% | Form 8-K (tm222755d1_ex99-1.htm, filed 2022-02-03) ↗ |
| FY2019 | Dec 31, 2019 | 306 | +17.7% | Form 8-K (tm213179d2_ex99-1.htm, filed 2021-02-04) ↗ |
| FY2018 | Dec 31, 2018 | 260 | +23.8% | Form 8-K (tm206551d1_ex99-1.htm, filed 2020-02-05) ↗ |
| FY2017 | Dec 31, 2017 | 210 | +36.4% | Form 8-K (a19-3795_1ex99d1.htm, filed 2019-02-01) ↗ |
| FY2016 | Dec 31, 2016 | 154 | – | Form 10-K (filed 2019-02-27) ↗ |
Breakdown
What makes up belsomra (suvorexant — insomnia orexin receptor antagonist) — worldwide sales ($m)
- Belsomra (suvorexant — insomnia orexin receptor antagonist) — U.S. sales ($M)82 · FY2025
- Belsomra (suvorexant — insomnia orexin receptor antagonist) — International sales ($M)104 · FY2025
- Belsomra (suvorexant — insomnia orexin receptor antagonist) — Worldwide reported growth YoY (%)-16.0% · FY2025
- Belsomra (suvorexant — insomnia orexin receptor antagonist) — Worldwide constant-currency (ex-exchange) growth YoY (%)-16.0% · FY2025
Cite this data
StockData. (2026). Merck Belsomra (suvorexant — insomnia orexin receptor antagonist) — Worldwide sales ($M) ($M), annual FY2016–FY2025 [Data set]. Compiled from Merck SEC filings and investor materials. https://stockdatahq.com/stocks/mrk/kpis/rev_belsomra
See every metric in the Merck KPI table. Data updated Oct 26, 2026.